Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.
Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- Check7 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
- Check14 days agoChange DetectedThe website has been updated from version 2.12.2 to 2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedNo new additions were noted, but a significant section of content related to downloading data formats and selecting study fields has been removed.SummaryDifference14%
- Check36 days agoChange DetectedA new study on Gilteritinib in combination with Ivosidenib or Enasidenib for Acute Myeloid Leukemia has been added, while a previous study from September 2024 has been removed.SummaryDifference1%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new download options in CSV, JSON, RIS, and FHIR formats, along with a comprehensive selection of data fields for studies.SummaryDifference16%
- Check50 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.3%
Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.